KFMI files for listing on HKEX: No.2 in sputter targets; CMS sole sponsor
NewTimeSpace News: On 12 November 2026, Konfoong Materials International Co., Ltd. (A-share stock code: 300666.SZ) filed an application for a Main Board listing with the Stock Exchange of Hong Kong, with China Merchants Securities International as sole sponsor. According to the prospectus, the Company focuses on core materials and key components for the semiconductor industry and ranked second among global ultra-high purity metal sputter target suppliers by 2025 revenue.
The prospectus stated that the Company has worked in ultra-high purity metal sputter targets for more than two decades and has built three platform capabilities in materials, equipment and processes around global customers and quality management, extending them into semiconductor precision components. In 2008, the Company completed certification and began supplying ultra-high purity metal sputter targets to Customer A, a leading global wafer foundry headquartered in Taiwan, China. According to Frost and Sullivan, it is the first Chinese company certified to supply such targets to all of the global top ten integrated device manufacturers and top ten wafer foundries.
According to Frost and Sullivan, the Company ranked second among global ultra-high purity metal sputter target suppliers by revenue for four consecutive years from 2022 to 2025, with a 10.3% global market share in 2025 and a 14.9% share of the global market for targets used in semiconductor chips; the top three suppliers together held about 42.8% that year. In 2025, the Company ranked third among domestic suppliers in China's semiconductor precision components market with a 1.4% share, and first among domestic suppliers in China's showerhead market. As at the latest practicable date, it held 1,085 granted patents worldwide, including 595 invention patents.
- AB&B BIO-TECH-B (02627.HK): Adsorbed Tetanus Vaccine Wins CDE IND Clearance
- BOCOM INTL (03329.HK): Buys US$12m Standard Chartered Notes for HK$93.6m
- HENGRUI PHARMA (01276.HK): Six Drugs Cleared for Clinical Trials, Including Two ADCs
- JLMAG (06680.HK): Baotou 20,000-Tonne Rare-Earth Magnet Project Passes Fire Inspection
- ZHAOKE OPHTH-B (06622.HK): Dry Eye Drug Jingyuling Wins NMPA Approval